EXECUTIVE COMMITTEE

Chair: Russell H. Plumb, MBA; President and Chief Executive Officer, Inhibitex Inc.

Charles Craig; President, Georgia Bio

Ed Shutter; President & Chief Executive Officer, Squire Pharmaceuticals

Laurence Downey; President, Berkshire Pharma Consulting

Margaret Poole; Chief Executive Officer, Informed Horizons

John W. Sharkey, PhD; Executive Vice President, Business Development, Shionogi Pharma, Inc.

Maria Thacker; Marketing Director, Georgia Bio

PROGRAM COMMITTEE

Co-Chair: Laurence Downey; President, Berkshire Pharma Consulting

Co-Chair: Ed Schutter; President & Chief Executive Officer, Squire Pharmaceuticals

Clifton A. Baile, PhD; Professor and GRA Eminent Scholar, University of Georgia

Steve Damon; VP Business Development, Altea Therapeutics

Al Heacox; Sr. VP Research and Development, CryoLife

Cinda Herndon-King, PhD; Director, Education Programs, Georgia Bio

H. Lee Herron, DVM; VP Commercialization, Georgia Research Alliance

Rebecca “Becky” J. Kaufman; Partner, King & Spalding

Margaret K. Offermann; Deputy National Vice President for Research, American Cancer Society

Joseph M. Patti, MSPH, PhD; Co-Founder, Chief Scientific Officer and Sr. VP Research and
Development, Inhibitex, Inc.

John P. Richard; Managing Director, Georgia Venture Partners

Mark L. Rosenberg, MD, MPP; President and Chief Executive Officer, The Task Force for
Global Health

David R. Stern; Senior Vice President, Scientific Affairs, CardioMEMS

Stacy Williams Shuker, PhD; Director, Center of Innovation for Life Sciences

SPONSORSHIP COMMITTEE

Thomas H. Callaway; Chief Executive Officer, AerovectRX

Charles Craig; President, Georgia Bio

John W. Sharkey; VP Business Development, Shionogi Pharma, Inc.

Kirk Dornbush; President, Iconic Therapeutics